Job Trends
Looking for quality assurance jobs in the biopharma industry? Check out these five top companies hiring life sciences professionals like you.
Labor Market Reports
Year-over-year BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the first quarter of 2025.
The 9% average salary increase from 2023 to 2024 was the largest for life sciences professionals since 2021. Several factors could be behind the spike, including companies providing higher pay because bonuses and stock compensation went down.
Now Hiring
Looking for a biopharma job in San Francisco? Check out the BioSpace list of 10 companies hiring life sciences professionals like you.
Although the job market did not pick up in April, layoffs were down year over year and month over month, according to BioSpace tallies. Meanwhile, Amgen, Novartis, Regeneron and Roche announced U.S. manufacturing investments that are sparking job creation.
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Career Advice
Getting job-hunting and career advice is hard, especially when you get it from those who have worked for decades. Some advice is still helpful today, like making a good impression, but others are considered counter-productive.
THE LATEST
September is turning out to be a busy month for the U.S. Food and Drug Administration. Here’s a look at this week’s schedule for PDUFA dates.
It was a very busy week for clinical trial announcements, although there were only three that were COVID-19-related. Here’s a look.
Mammoth will use the funds to build and broaden its stable of next-generation CRISPR products to detect and cure various diseases.
BioLabs is opening its next hub in Dallas in a 37,000-square-foot flexible life science facility. The Biotech+ Hub can accommodate 35 startups, for which it’s now accepting applications.
The 146,000 square foot facility will benefit Umoja Biopharma to eliminate crucial CAR-T production barriers. There’s a lot more going on, know everything here.
Laronde has managed to secure as much as $440 million from a Series B financing round to support as many as 100 Endless RNA (eRNA) products and drug programs over the next decade.
An alleged plan by Johnson & Johnson to spin off a company solely responsible for its talc-based products in order to mitigate lawsuit damages is still on the table following a ruling by a federal judge.
Gilead won the most recent battle when a U.S. appeals court threw out a $1.2 billion ruling against the company.
It was a busy week for clinical trial news. Here’s a look.
Lycia will be receiving a $35 million upfront payment from Lilly and is eligible for over $1.6 billion in potential milestone payments.